New nuclear imaging studies available for clinical use.
Several new diagnostic drugs for use in nuclear medicine have become commercially available in the past year. Recently revised Nuclear Regulatory Commission regulations pertaining to nuclear imaging studies are being adopted by the Iowa Department of Public Health. The author reviews clinical uses of the new drugs, and changes in regulations that allow broader use of existing radiopharmaceuticals.
Ponto
J
J
University of Iowa Hospitals and Clinics.
D004176:Dipyridamole; D006801:Humans; D007484:Iowa; D009842:Oligopeptides; D015609:Organotechnetium Compounds; D010091:Oximes; D011356:Product Labeling / Q000331:legislation & jurisprudence; D011850:Radioactive Waste / Q000331:legislation & jurisprudence*; D017263:Technetium Tc 99m Mertiatide; D017256:Technetium Tc 99m Sestamibi; D014481:United States; D014486:United States Food and Drug Administration
D009842:Oligopeptides; D015609:Organotechnetium Compounds; D010091:Oximes; D011850:Radioactive Waste; D017263:Technetium Tc 99m Mertiatide; D004176:Dipyridamole; D017256:Technetium Tc 99m Sestamibi; C060156:technetium Tc 99m teboroxime